A Phase II, Single Arm Study Of CP-751,871 In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum.
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2014
At a glance
- Drugs Figitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 25 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.